• Je něco špatně v tomto záznamu ?

Transperineal or Transrectal Magnetic Resonance Imaging-targeted Biopsy for Prostate Cancer Detection

R. Diamand, K. Guenzel, G. Mjaess, Y. Lefebvre, M. Ferriero, G. Simone, A. Fourcade, G. Fournier, AP. Bui, F. Taha, M. Oderda, P. Gontero, K. Rysankova, A. Bernal-Gomez, A. Mastrorosa, JB. Roche, G. Fiard, R. Abou Zahr, G. Ploussard, O. Windisch,...

. 2024 ; 10 (5) : 805-811. [pub] 20240319

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25004143

BACKGROUND AND OBJECTIVE: A notable paradigm shift has emerged in the choice of prostate biopsy approach, with a transition from transrectal biopsy (TRBx) to transperineal biopsy (TPBx) driven by the lower risk of severe urinary tract infections. The impact of this change on detection of clinically significant prostate cancer (csPCa) remains a subject of debate. Our aim was to compare the csPCa detection rate of TRBx and TPBx. METHODS: Patients who underwent magnetic resonance imaging (MRI)-targeted and systematic biopsies for clinically localized PCa at 15 European referral centers from 2016 to 2023 were included. A propensity score matching (PSM) analysis was performed to minimize selection biases. Logistic regression models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). KEY FINDINGS AND LIMITATIONS: Of 3949 patients who met the study criteria, 2187 underwent TRBx and 1762 underwent TPBx. PSM resulted in 1301 matched pairs for analysis. Patient demographics and tumor characteristics were comparable in the matched cohorts. TPBx versus TRBx was associated with greater detection of csPCa, whether defined as International Society of Urological Pathology grade group ≥2 (51% vs 45%; OR 1.37, 95% CI 1.15-1.63; p = 0.001) or grade group ≥3 (29% vs 23%; OR 1.38, 95% CI 1.13-1.67; p = 0.001). Similar results were found when considering MRI-targeted biopsy alone and after stratifying patients according to tumor location, Prostate Imaging-Reporting and Data System score, and clinical features. Limitations include the retrospective nature of the study and the absence of centralized MRI review. CONCLUSIONS: Our findings bolster existing understanding of the additional advantages offered by TPBx. Further randomized trials to fully validate these findings are awaited. PATIENT SUMMARY: We compared the rate of detection of clinically significant prostate cancer with magnetic resonance imaging (MRI)-guided biopsies in which the sample needle is passed through the perineum or the rectum. Our results suggest that the perineal approach is associated with better detection of aggressive prostate cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004143
003      
CZ-PrNML
005      
20250206105951.0
007      
ta
008      
250121s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euf.2024.03.003 $2 doi
035    __
$a (PubMed)38508895
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Diamand, Romain $u Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: romain.diamand@hubruxelles.be
245    10
$a Transperineal or Transrectal Magnetic Resonance Imaging-targeted Biopsy for Prostate Cancer Detection / $c R. Diamand, K. Guenzel, G. Mjaess, Y. Lefebvre, M. Ferriero, G. Simone, A. Fourcade, G. Fournier, AP. Bui, F. Taha, M. Oderda, P. Gontero, K. Rysankova, A. Bernal-Gomez, A. Mastrorosa, JB. Roche, G. Fiard, R. Abou Zahr, G. Ploussard, O. Windisch, Q. Novello, D. Benamran, G. Delavar, J. Anract, N. Barry Delongchamps, A. Halinski, C. Dariane, J. Benijts, G. Assenmacher, T. Roumeguère, A. Peltier
520    9_
$a BACKGROUND AND OBJECTIVE: A notable paradigm shift has emerged in the choice of prostate biopsy approach, with a transition from transrectal biopsy (TRBx) to transperineal biopsy (TPBx) driven by the lower risk of severe urinary tract infections. The impact of this change on detection of clinically significant prostate cancer (csPCa) remains a subject of debate. Our aim was to compare the csPCa detection rate of TRBx and TPBx. METHODS: Patients who underwent magnetic resonance imaging (MRI)-targeted and systematic biopsies for clinically localized PCa at 15 European referral centers from 2016 to 2023 were included. A propensity score matching (PSM) analysis was performed to minimize selection biases. Logistic regression models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). KEY FINDINGS AND LIMITATIONS: Of 3949 patients who met the study criteria, 2187 underwent TRBx and 1762 underwent TPBx. PSM resulted in 1301 matched pairs for analysis. Patient demographics and tumor characteristics were comparable in the matched cohorts. TPBx versus TRBx was associated with greater detection of csPCa, whether defined as International Society of Urological Pathology grade group ≥2 (51% vs 45%; OR 1.37, 95% CI 1.15-1.63; p = 0.001) or grade group ≥3 (29% vs 23%; OR 1.38, 95% CI 1.13-1.67; p = 0.001). Similar results were found when considering MRI-targeted biopsy alone and after stratifying patients according to tumor location, Prostate Imaging-Reporting and Data System score, and clinical features. Limitations include the retrospective nature of the study and the absence of centralized MRI review. CONCLUSIONS: Our findings bolster existing understanding of the additional advantages offered by TPBx. Further randomized trials to fully validate these findings are awaited. PATIENT SUMMARY: We compared the rate of detection of clinically significant prostate cancer with magnetic resonance imaging (MRI)-guided biopsies in which the sample needle is passed through the perineum or the rectum. Our results suggest that the perineal approach is associated with better detection of aggressive prostate cancer.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory prostaty $x patologie $x diagnostické zobrazování $7 D011471
650    12
$a ultrazvukem navigovaná biopsie $x metody $7 D061705
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a perineum $7 D010502
650    12
$a magnetická rezonanční tomografie $x metody $7 D008279
650    12
$a rektum $x patologie $x diagnostické zobrazování $7 D012007
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a prostata $x patologie $x diagnostické zobrazování $7 D011467
650    _2
$a magnetická rezonance intervenční $x metody $7 D053783
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Guenzel, Karsten $u Department of Urology, Vivantes Klinikum am Urban, Berlin, Germany
700    1_
$a Mjaess, Georges $u Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
700    1_
$a Lefebvre, Yolène $u Department of Radiology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
700    1_
$a Ferriero, Mariaconsiglia $u Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
700    1_
$a Simone, Giuseppe $u Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
700    1_
$a Fourcade, Alexandre $u Department of Urology, Hôpital Cavale Blanche, CHRU Brest, Brest, France
700    1_
$a Fournier, Georges $u Department of Urology, Hôpital Cavale Blanche, CHRU Brest, Brest, France
700    1_
$a Bui, Alexandre-Patrick $u Department of Urology, Centre Hospitalier Universitaire de Reims, Reims, France
700    1_
$a Taha, Fayek $u Department of Urology, Centre Hospitalier Universitaire de Reims, Reims, France
700    1_
$a Oderda, Marco $u Department of Urology, Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
700    1_
$a Gontero, Paolo $u Department of Urology, Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
700    1_
$a Rysankova, Katerina $u Department of Urology, University Hospital Ostrava, Ostrava, Czechia; Department of Surgical Studies, Faculty of Medicine, Ostrava University, Ostrava, Czechia
700    1_
$a Bernal-Gomez, Adrian $u Department of Urology, Clinique Saint-Augustin, Bordeaux, France
700    1_
$a Mastrorosa, Alessandro $u Department of Urology, Clinique Saint-Augustin, Bordeaux, France
700    1_
$a Roche, Jean-Baptiste $u Department of Urology, Clinique Saint-Augustin, Bordeaux, France
700    1_
$a Fiard, Gaelle $u Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, Grenoble, France
700    1_
$a Abou Zahr, Rawad $u Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France
700    1_
$a Ploussard, Guillaume $u Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France
700    1_
$a Windisch, Olivier $u Department of Urology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
700    1_
$a Novello, Quentin $u Department of Urology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
700    1_
$a Benamran, Daniel $u Department of Urology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
700    1_
$a Delavar, Gina $u Departement of Urology, Hôpital Cochin, Paris, France
700    1_
$a Anract, Julien $u Departement of Urology, Hôpital Cochin, Paris, France
700    1_
$a Barry Delongchamps, Nicolas $u Departement of Urology, Hôpital Cochin, Paris, France
700    1_
$a Halinski, Adam $u Department of Urology, Klinika Wisniowa, Zielona Góra, Poland
700    1_
$a Dariane, Charles $u Department of Urology, Hôpital Européen Georges-Pompidou, Université de Paris, Paris, France
700    1_
$a Benijts, Jan $u Department of Urology, Cliniques de l'Europe-Saint Elisabeth, Brussels, Belgium
700    1_
$a Assenmacher, Gregoire $u Department of Urology, Cliniques de l'Europe-Saint Elisabeth, Brussels, Belgium
700    1_
$a Roumeguère, Thierry $u Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
700    1_
$a Peltier, Alexandre $u Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
773    0_
$w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 10, č. 5 (2024), s. 805-811
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38508895 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206105946 $b ABA008
999    __
$a ok $b bmc $g 2263724 $s 1240150
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 10 $c 5 $d 805-811 $e 20240319 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace